Tests for ovarian reserve: Reliability and utility

Current Opinion in Obstetrics and Gynecology

Volumn 22, Issue 4, 2010, Pages 271-276

  Domingues, Thaís S ^a   Rocha, André M ^a   Serafini, Paulo C ^a,b  

^a Huntington Medicina Reprodutiva   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

antimullerian hormone; antral follicle count; in vitro fertilization; ovarian reserve tests; ovulation induction

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; FOLLITROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR;

ACCURACY; CANCER THERAPY; CONCEPTION; CORRELATION ANALYSIS; COST UTILITY ANALYSIS; COUNSELING; DIAGNOSTIC ACCURACY; ECHOGRAPHY; FEMALE FERTILITY; FERTILITY; FOLLICULAR PHASE; HORMONE BLOOD LEVEL; HUMAN; MENOPAUSE; OVARIAN FUNCTION TEST; OVARIAN RESERVE; OVARY FUNCTION; OVARY HYPERSTIMULATION; OVARY INSUFFICIENCY; OVULATION INDUCTION; PREDICTION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; BLOOD; FEMALE; FEMALE INFERTILITY; NEOPLASMS; OVARY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANTI-MULLERIAN HORMONE; FEMALE; FOLLICULAR PHASE; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; OVARY; OVULATION INDUCTION;

EID: 77954656646     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/GCO.0b013e32833b4f5c     Document Type: Review

References (68)

1. Leridon H. Demographic effects of the introduction of steroid contraception in developed countries. Hum Reprod Update 2006; 12:603-616.
2. Leridon H, Slama R. The impact of a decline in fecundity and of pregnancy postponement on final number of children and demand for assisted reproduction technology. Hum Reprod 2008; 23:1312-1319.
3. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update 2002; 8:141-154.
4. Gougeon A. Regulation of ovarian follicular development in primates: facts and hypotheses. Endocr Rev 1996; 17:121-155.
5. Broekmans FJ, Kwee J, Hendriks DJ, et al. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 2006; 12:685-718.
6. Baker TG. A quantitative and cytological study of germ cells in human ovaries. Proc R Soc Lond B Biol Sci 1963; 158:417-433.
7. Faddy MJ, Gosden RG, Gougeon A, et al. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992; 7:1342-1346.
8. Faddy MJ, Gosden RG. A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod 1996; 11:1484-1486.
9. Wallace WH, Kelsey TW. Human ovarian reserve from conception to the menopause. PLoS One 2010; 5:e8772.
10. Faddy MJ. Follicle dynamics during ovarian ageing. Mol Cell Endocrinol 2000; 163:43-48.
11. de Carvalho BR, Rosae Silva AC, Rosae Silva JC, et al. Ovarian reserve evaluation: state of the art. J Assist Reprod Genet 2008; 25:311-322.
12. Sills ES, Alper MM, Walsh AP. Ovarian reserve screening in infertility: practical applications and theoretical directions for research. Eur J Obstet Gynecol Reprod Biol 2009; 146:30-36.
13. Rosencrantz MA, Wachs DS, Coffler MS, et al. Comparison of inhibin B and estradiol responses to intravenous FSH in women with polycystic ovary syndrome and normal women. Hum Reprod 2010; 25:198-203.
14. Knauff EA, Eijkemans MJ, Lambalk CB, et al. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab 2009; 94:786-792.
15. Kwee J, Elting ME, Schats R, et al. Ovarian volume and antral follicle count for the prediction of low and hyper responders with in vitro fertilization. Reprod Biol Endocrinol 2007; 5:9.
16. Hendriks DJ, Kwee J, Mol BW, et al. Ultrasonography as a tool for the prediction of outcome in IVF patients: a comparative meta-analysis of ovarian volume and antral follicle count. Fertil Steril 2007; 87:764-775.
17. Jayaprakasan K, Campbell B, Hopkisson J, et al. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2008; 93:855-864.
18. Johnston RJ, Wallace WH. Normal ovarian function and assessment of ovarian reserve in the survivor of childhood cancer. Pediatr Blood Cancer 2009; 53:296-302.
19. Navot D, Rosenwaks Z, Margalioth EJ. Prognostic assessment of female fecundity. Lancet 1987; 2:645-647.
20. Maheshwari A, Gibreel A, Bhattacharya S, et al. Dynamic tests of ovarian reserve: a systematic review of diagnostic accuracy. Reprod Biomed Online 2009; 18:717-734.
21. Gupta S, Sharma D, Surti N, et al. Ovarian reserve testing: systematic review of the literature. Arch Med Sci 2009; 5:S143-S150.
22. de Koning CH, McDonnell J, Themmen AP, et al. The endocrine and follicular growth dynamics throughout the menstrual cycle in women with consistently or variably elevated early follicular phase FSH compared with controls. Hum Reprod 2008; 23:1416-1423.
23. Chuang CC, Chen CD, Chao KH, et al. Age is a better predictor of pregnancy potential than basal follicle-stimulating hormone levels in women undergoing in vitro fertilization. Fertil Steril 2003; 79:63-68.
24. Gomes CM, Serafini PC, Motta EL, et al. Administration of a pharmacophysiologic dose of recombinant human chorionic gonadotropin at menses promotes corpus luteum rescue. Int J Gynaecol Obstet 2010; 108:158-159.
25. Smotrich DB, Widra EA, Gindoff PR, et al. Prognostic value of day 3 estradiol on in vitro fertilization outcome. Fertil Steril 1995; 64:1136-1140.
26. Roberts JE, Spandorfer S, Fasouliotis SJ, et al. Taking a basal folliclestimulating hormone history is essential before initiating in vitro fertilization. Fertil Steril 2005; 83:37-41.
27. Levy MJ, Smotrich DB, Widra EA, et al. The predictive value of serum progesterone and 17-OH progesterone levels on in vitro fertilization outcome. J Assist Reprod Genet 1995; 12:161-166.
28. Buyalos RP, Daneshmand S, Brzechffa PR. Basal estradiol and folliclestimulating hormone predict fecundity in women of advanced reproductive age undergoing ovulation induction therapy. Fertil Steril 1997; 68:272-277.
29. Vale W, Rivier C, Hsueh A, et al. Chemical and biological characterization of the inhibin family of protein hormones. Recent Prog Horm Res 1988; 44:1-34.
30. Sowers M, McConnell D, Gast K, et al. Anti-Mullerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril (in press). doi: 10.1016/ j.fertnstert.2009.07.1674.
31. Sowers MR, Eyvazzadeh AD, McConnell D, et al. Antimullerian hormone and inhibin B in the definition of ovarian aging and the menopause transition. J Clin Endocrinol Metab 2008; 93:3478-3483.
32. Seifer DB, Lambert-Messerlian G, Hogan JW, et al. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertil Steril 1997; 67:110-114.
33. van Rooij IA, Broekmans FJ, Scheffer GJ, et al. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 2005; 83:979-987.
34. Burger HG, Hale GE, Robertson DM, et al. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne Women's Midlife Health Project. Hum Reprod Update 2007; 13:559-565.
35. Penarrubia J, Fabregues F, Manau D, et al. Basal and stimulation day 5 anti-Mullerian hormone serum concentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist: gonadotropin treatment. Hum Reprod 2005; 20:915-922.
36. Weenen C, Laven JS, Von Bergh AR, et al. Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 2004; 10:77-83.
37. Broekmans FJ, Visser JA, Laven JS, et al. Anti-Mullerian hormone and ovarian dysfunction. Trends Endocrinol Metab 2008; 19:340-347.
38. Gnoth C, Schuring AN, Friol K, et al. Relevance of anti-Mullerian hormone measurement in a routine IVF program. Hum Reprod 2008; 23:1359-1365.
39. Elgindy EA, El-Haieg DO, El-Sebaey A. Anti-Mullerian hormone: correlation of early follicular, ovulatory and midluteal levels with ovarian response and cycle outcome in intracytoplasmic sperm injection patients. Fertil Steril 2008; 89:1670-1676.
40. Visser J. Role of anti-Mullerian hormone in follicle recruitment and maturation. J Gynecol Obstet Biol Reprod (Paris) 2006; 35:2S30-32S34.
41. Themmen AP. Anti-Mullerian hormone: its role in follicular growth initiation and survival and as an ovarian reserve marker. J Natl Cancer Inst Monogr 2005; 18-21.
42. Wunder DM, Bersinger NA, Yared M, et al. Statistically significant changes of antimullerian hormone and inhibin levels during the physiologic menstrual cycle in reproductive age women. Fertil Steril 2008; 89:927-933.
43. Tsepelidis S, Devreker F, Demeestere I, et al. Stable serum levels of anti-Mullerian hormone during the menstrual cycle: a prospective study in normoovulatory women. Hum Reprod 2007; 22:1837-1840.
44. van Disseldorp J, Lambalk CB, Kwee J, et al. Comparison of inter- and intracycle variability of anti-Mullerian hormone and antral follicle counts. Hum Reprod 2010; 25:221-227.
45. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2009; 16:113-130.
46. La Marca A, Giulini S, Tirelli A, et al. Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology. Hum Reprod 2007; 22:766-771.
47. La Marca A, Stabile G, Artenisio AC, et al. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod 2006; 21:3103-3107.
48. Jayaprakasan K, Deb S, Batcha M, et al. The cohort of antral follicles measuring 2-6mm reflects the quantitative status of ovarian reserve as assessed by serum levels of anti-Mullerian hormone and response to controlled ovarian stimulation. Fertil Steril 2009. doi: 10.1016/j.fertnstert.2009.10.1022.
49. Jayaprakasan K, Campbell B, Hopkisson J, et al. A prospective, comparative analysis of anti-Mullerian hormone, inhibin-B, and three-dimensional ultrasound determinants of ovarian reserve in the prediction of poor response to controlled ovarian stimulation. Fertil Steril 2010; 93:855-864.
50. Gibreel A, Maheshwari A, Bhattacharya S, et al. Ultrasound tests of ovarian reserve; a systematic review of accuracy in predicting fertility outcomes. Hum Fertil (Camb) 2009; 12:95-106.
51. Parazzini F. Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas 2007; 56:280-287.
52. Plante BJ, Cooper GS, Baird DD, et al. The impact of smoking on antimullerian hormone levels inwomenaged38to50years.Menopause2010;17:571-576.
53. van Disseldorp J, Faddy MJ, Themmen AP, et al. Relationship of serum antimullerian hormone concentration to age at menopause. J Clin Endocrinol Metab 2008; 93:2129-2134.
54. Partridge AH, Ruddy KJ, Gelber S, et al. Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertil Steril 2009. doi: 10.1016/j.fertnstert.2009.03.045.
55. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod 2009; 24:982-990.
56. Williams D, Crofton PM, Levitt G. Does ifosfamide affect gonadal function? Pediatr Blood Cancer 2008; 50:347-351.
57. Lie Fong S, Lugtenburg PJ, Schipper I, et al. Antimullerian hormone as a marker of ovarian function in women after chemotherapy and radiotherapy for haematological malignancies. Hum Reprod 2008; 23:674-678.
58. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007; 110:2222-2229. (Pubitemid 350100744)
59. Su HI, Sammel MD, Green J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer 2010; 116:592-599.
60. Maman E, Prokopis K, Levron J, et al. Does controlled ovarian stimulation prior to chemotherapy increase primordial follicle loss and diminish ovarian reserve? An animal study. Hum Reprod 2009; 24:206-210.
61. Muttukrishna S, McGarrigle H, Wakim R, et al. Antral follicle count, antimullerian hormone and inhibin B: predictors of ovarian response in assisted reproductive technology? BJOG 2005; 112:1384-1390.
62. Melo MA, Garrido N, Alvarez C, et al. Antral follicle count (AFC) can be used in the prediction of ovarian response but cannot predict the oocyte/embryo quality or the in vitro fertilization outcome in an egg donation program. Fertil Steril 2009; 91:148-156.
63. Seifer DB, Maclaughlin DT. Mullerian Inhibiting Substance is an ovarian growth factor of emerging clinical significance. Fertil Steril 2007; 88:539-546.
64. La Marca A, Sighinolfi G, Radi D, et al. Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 2010; 16:113-130.
65. Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles- implications for individualization of therapy. Hum Reprod 2007; 22:2414-2421.
66. Wunder DM, Guibourdenche J, Birkhauser MH, et al. Anti-Mullerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2008; 90:2203-2210.
67. Lee TH, Liu CH, Huang CC, et al. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 2009; 7:100.
68. Silberstein T, MacLaughlin DT, Shai I, et al. Mullerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Hum Reprod 2006; 21:159-163.